Session 3: Monitoring and Managing Infections in Patients with MM Treated with Bispecific Antibodies : Episode 4
Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.
Video Player is loading.
EP: 1.Overview of Bispecific Antibodies in Multiple Myeloma Treatment
EP: 2.Infection Patterns of Bispecific Antibodies in Multiple Myeloma Treatment
EP: 3.Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple Myeloma
Now Viewing
EP: 4.Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
EP: 5.Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
EP: 6.Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
EP: 7.Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
EP: 8.Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
EP: 9.Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
EP: 10.Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
EP: 11.Recap: Mitigation of CRS and ICANS During Bispecific Treatment in Multiple Myeloma
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
JNJ-5322 Shows Efficacy in Later-Line Multiple Myeloma
MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Related Content
